US FDA Won't Budge On Nitrosamines Compliance Despite Complaints Of Possible Drug Shortages
Executive Summary
Industry requests for deadline extensions, short-duration adjustments and other accommodations go nowhere as FDA expresses concerns about nitrosamines’ mutagenic potency.
You may also be interested in...
Testing For Nitrosamine Impurities: Deadlines And Updates In EU, US, Canada, Malaysia, Australia
Drug companies deadlines are nearing to meet regulatory requirements relating to nitrosamine impurities found in their products as guidelines are being revised or re-published.
US FDA Suggests Adding Antioxidants To Drug Formulations To Mitigate Nitrosamine Risks
Agency recommends “mitigation strategies” also including designing formulations that incorporate excipients such as sodium carbonate which modify the micro-environment to neutral or basic pH.
With 'No Transparency To Drug Quality' In US, Requiring Independent Testing Needed – Valisure
“I think one of the big issues of how the FDA regulatory framework works is that it's very rare that the FDA actually tests anything. It's all self-reported testing, by manufacturers that are also selling the product,” says Valisure CEO David Light.